VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, Jan. 22, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2023 on Monday January 29, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday January 30, 2024 at 8.30am (ET).
To join the conference call without operator assistance, you may register and enter your phone number at https://emportal.ink/3RSJ3aC to receive an instant automated call back.
You can also dial direct to be entered to the call by an Operator. (Traditional conference call instructions here):
Conference ID: |
50959607 |
Date: |
Tuesday, January 30, 2024 |
Time: |
8:30am ET |
Dial-in numbers: |
1-888-664-6392 or 416-764-8659 |
Audio replay numbers: |
1-888-390-0541 or 416-764-8677 |
Replay code: |
959607 # |
A live audio webcast of the conference call will be available via:
https://app.webinar.net/5z6nmw5MNAw
Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
SOURCE Valeo Pharma Inc.
Steve Saviuk, CEO, 514-693-8830, [email protected] or Pascal Tougas, Chief Financial Officer, 438-870-3079, [email protected] or Frederic Dumais, Director, Communications and Investor Relations, 514-693-8847, [email protected]
Share this article